



## **PD Dr. Inga Bekes**

chief of service

Brustzentrum St.Gallen, Medizinische Onkologie und Hämatologie · Dept. IV,  
Dept. I

### **Contact**

PD Dr. Inga Bekes  
Rorschacherstrasse 95  
9007 St.Gallen  
Switzerland

T +41 71 494 18 70  
inga.bekes@kssg.ch

### **Homepage**

[www.kssg.ch/brustzentrum](http://www.kssg.ch/brustzentrum)

### **Units**

Brustzentrum St.Gallen, Medizinische Onkologie und Hämatologie

### **Profile Function**

chief of service

## Publications (39)

Reimer T, Stachs A, Veselinovic K, Kühn T, Heil J, Polata S, Marme F, Müller T, Hildebrandt G, Krug D, Ataseven B, Reitsamer R, Ruth S, Denkert C, Bekes I, Zahm D, Thill M, Golatta M, Holtschmidt J, Knauer M, Nekljudova V, Loibl S, Gerber B. Axillary Surgery in Breast Cancer – Primary Results of the INSEMA Trial. *N Engl J Med* 2024

Pfob A, Cai L, Schneeweiss A, Rauch G, Thomas B, Schaefgen B, Kümmel S, Reimer T, Hahn M, Thill M, Blohmer J, Hackmann J, Malter W, Bekes I, Friedrichs K, Wojcinski S, Joos S, Paepke S, Degenhardt T, Rom J, Rody A, van Mackelenbergh M, Banys-Paluchowski M, Große R, Reinisch M, Karsten M, Sidey-Gibbons C, Wallwiener M, Golatta M, Heil J. ASO Visual Abstract: Minimally-Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment-A New Concept. *Ann Surg Oncol* 2023

Kersten J, Fink V, Kersten M, May L, Nunn S, Tadic M, Huober J, Bekes I, Radermacher M, Hombach V, Rottbauer W, Buckert D. CMR reveals myocardial damage from cardiotoxic oncologic therapies in breast cancer patients. *Int J Cardiovasc Imaging* 2023

Weber W, Heidinger M, Hayoz S, Matrai Z, Tausch C, Henke G, Zwahlen D, Gruber G, Zimmermann F, Montagna G, Andreozzi M, Goldschmidt M, Schulz C, Müller A, Ackerknecht M, Tampaki E, Bjelic-Radisic V, Kurzeder C, Sávolt Á, Smanyakó V, Hagen D, Müller D, Gnant M, Loibl S, Fitzal F, Markellou P, Bekes I, Egle D, Heil J, Knauer M. ASO Visual Abstract: Impact of Imaging-Guided Localization on Performance of Tailored Axillary Surgery in Patients with Clinically Node-Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101). *Ann Surg Oncol* 2023

Pfob A, Cai L, Schneeweiss A, Rauch G, Thomas B, Schaefgen B, Kümmel S, Reimer T, Hahn M, Thill M, Blohmer J, Hackmann J, Malter W, Bekes I, Friedrichs K, Wojcinski S, Joos S, Paepke S, Degenhardt T, Rom J, Rody A, van Mackelenbergh M, Banys-Paluchowski M, Große R, Reinisch M, Karsten M, Sidey-Gibbons C, Wallwiener M, Golatta M, Heil J. Minimally Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment: A New Concept. *Ann Surg Oncol* 2023

Weber W, Heidinger M, Hayoz S, Matrai Z, Tausch C, Henke G, Zwahlen D, Gruber G, Zimmermann F, Montagna G, Andreozzi M, Goldschmidt M, Schulz C, Müller A, Ackerknecht M, Tampaki E, Bjelic-Radisic V, Kurzeder C, Sávolt Á, Smanyakó V, Hagen D, Müller D, Gnant M, Loibl S, Fitzal F, Markellou P, Bekes I, Egle D, Heil J, Knauer M. Impact of Imaging-Guided Localization on Performance of Tailored Axillary Surgery in Patients with Clinically Node-Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101). *Ann Surg Oncol* 2023

Bekes I, Huober J. Extended Adjuvant Endocrine Therapy in Early Breast Cancer Patients-Review and Perspectives. *Cancers (Basel)* 2023; 15

Tausch C, Däster K, Hayoz S, Matrai Z, Fitzal F, Henke G, Zwahlen D, Gruber G, Zimmermann F, Andreozzi M, Goldschmidt M, Schulz C, Maggi N, Saccilotto R, Heidinger M, Müller A, Tampaki E, Bjelic-Radisic V, Sávolt Á, Smanyakó V, Hagen D, Müller D, Gnant M, Loibl S, Markellou P, Bekes I, Egle D, Ruhstaller T, Muenst S, Kümmel S, Vrieling C, Satler R, Becciolini C, Bucher S, Kurzeder C, Simonson C, Fehr P, Gabriel N, Maráz R, Sarlos D, Dedes K, Leo C, Berclaz G, Fansa H, Hager C, Reisenberger K, Singer C, Montagna G, Reitsamer R, Winkler J, Lam G, Fehr M, Naydina T, Kohlik M, Clerc K, Ostapenko V, Lelièvre L, Heil J, Knauer M, Weber W. Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101). *Breast Cancer Res Treat* 2023; 201:215-225.

Hämmerli Keller K, Markus A, Berger T, Huober J, Bekes I, Schmidt R, Gysin C, Schönenberger M, Germann N, Bürgin M, Diethelm S, Schmid D (2022). Mind-Body Online-Therapie im somatischen Setting – Entwicklung einer Online-Intervention im Rahmen der onkologischen Gynäkologie.

Baaken D, Schmidberger H, Blettner M, Wiegel T, Bartkowiak D, Renner J, Ghilescu V, Merz T, Mose S, Mayr M, Wöckel A, Janni W, Schwentner L, Bekes I, Schmidt M, Merzenich H, Wollschläger D. A nested case-control study on radiation dose-response for cardiac events in breast cancer patients in Germany. *Breast* 2022; 65:1-7.

Huebner H, Tesch H, Brucker S, Blohmer J, Fehm T, Heinrich G, Rezai M, Beckmann M, Fasching P, Janni W, Schneeweiss A, Nabieva N, Jückerstock J, Häberle L, Müller V, Schrader I, Lorenz R, Forstbauer H, Fink V, Schochter F, Bekes I, Mahner S, Rack B. MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients. *Cancers (Basel)* 2022; 14

Pfob A, Joos S, Paepke S, Degenhardt T, Rom J, Rody A, van Mackelenbergh M, Banys-Paluchowski M, Große R, Reinisch M, Karsten M, Golatta M, Wojcinski S, Friedrichs K, Bekes I, Sidey-Gibbons C, Rauch G, Thomas B, Schaeffgen B, Kuemmel S, Reimer T, Hahn M, Thill M, Blohmer J, Hackmann J, Malter W, Heil J. Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery. *J Clin Oncol* 2022:JCO2102439.

Merzenich H, Wollschläger D, Blettner M, Wiegel T, Bartkowiak D, Woeckel A, Janni W, Schwentner L, Bekes I, Schmidt M, Baaken D, Schmidberger H. Cardiac late effects after modern 3D-conformal radiotherapy in breast cancer patients: a retrospective cohort study in Germany (ESCaRa). *Breast Cancer Res Treat* 2021

De Gregorio A, Friedl T, Hering E, Widschwendter P, De Gregorio N, Bekes I, Janni W, Davut D, Huober J. Ki67 as Proliferative Marker in Patients with Early Breast Cancer and Its Association with Clinicopathological Factors. *Oncology* 2021; 99:780-789.

Friedl T, Tesch H, Mahner S, Brucker S, Heinrich G, Häberle L, Fasching P, Beckmann M, Coleman R, Janni W, Schneeweiss A, Jückerstock J, Fehm T, Müller V, Lichtenegger W, Blohmer J, Lorenz R, Forstbauer H, Fink V, Bekes I, Huober J, Rack B. Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial. *JAMA Oncol* 2021; 7:1149-1157.

Wischnewsky M, Wöckel A, Kreienberg R, Janni W, Wolters R, Blettner M, Müller-Reiter M, Kiesel M, Bekes I, Salmen J, Davut D, Joukadar R, De Gregorio A, Diessner J, Schwentner L, Ebner F. BRENDA-Score, a Highly Significant, Internally and Externally Validated Prognostic Marker for Metastatic Recurrence: Analysis of 10,449 Primary Breast Cancer Patients. *Cancers (Basel)* 2021; 13

Herbert S, Schwentner L, Fink V, Bekes I, Leinert E, Lato K, Polasik A, Schochter F, Singer S, Salmen J, Diessner J, Stüber T, Wöckel A, Kreienberg R, Kühn T, Flock F, Felberbaum R, Janni W, Curtaz C, Kiesel M, BRENDA study group. To which extent do breast cancer survivors feel well informed about disease and treatment 5 years after diagnosis?. *Breast Cancer Res Treat* 2020; 185:677-684.

De Gregorio A, Schneeweiss A, Tesch H, Mahner S, Brucker S, Blohmer J, Fehm T, Heinrich G, Lato K, Beckmann M, Rack B, Andergassen U, Bekes I, Fink V, Häberle L, Fasching P, Müller V, Schrader I, Lorenz R, Forstbauer H, Friedl T, Bauer E, De Gregorio N, Deniz M, Janni W. Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial. *Breast Cancer Res* 2020; 22:111.

Heil J, Friedrichs K, Wojcinski S, Joos S, Paepke S, Ditsch N, Rody A, Große R, van Mackelenbergh M, Reinisch M, Karsten M, Golatta M, Bekes I, Malter W, Hackmann J, Pfob A, Sinn H, Rauch G, Bach P, Thomas B, Schaeffgen B, Kuemmel S, Reimer T, Hahn M, Thill M, Blohmer J, RESPONDER Investigators. Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy: Oral Presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, Program Number GS5-03. *Ann Surg* 2020

Hildebrandt G, Loibl S, Bekes I, Nekljudova V, Heil J, Reitsamer R, Kaiser J, Sedlmayer F, Zierhut D, Kühn T, Wolter K, Krug D, Potenberg J, Gerber B, Stachs A, Reimer T. Central Review of Radiation Therapy Planning Among Patients with Breast-Conserving Surgery: Results from a Quality Assurance Process Integrated into the INSEMA Trial. *Int J Radiat Oncol Biol Phys* 2020; 107:683–693.

Bekes I, Janni W, Lato K, Kiechle M, Huober J, Dannecker C, Forstbauer H, Rack B, Harbeck N, Friedl T, Singer S, Eichler M, Fink V. Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial. *Clin Breast Cancer* 2020; 20:439–447.

Bekes I, Löb S, Holzheu I, Janni W, Baumann L, Wöckel A, Wulff C. Nectin-2 in ovarian cancer: How is it expressed and what might be its functional role?. *Cancer Sci* 2019; 110:1872–1882.

Ebner F, De Gregorio A, Schochter F, Bekes I, Janni W, Lato K. Effect of an Augmented Reality Ultrasound Trainer App on the Motor Skills Needed for a Kidney Ultrasound: Prospective Trial. *JMIR Serious Games* 2019; 7:e12713.

Cámara R, Singer S, Janni W, Rack B, Widschwendter P, Lato K, Fink V, Deniz M, Friedl T, Schwentner L, Bekes I. Quality of life during and after adjuvant anthracycline-taxane-based chemotherapy with or without Gemcitabine in high-risk early breast cancer: results of the SUCCESS A trial. *Breast Cancer Res Treat* 2019; 175:627–635.

Deniz M, Andergassen U, Steidl J, Trapp E, Fasching P, Häberle L, Beckmann M, Schneeweiss A, Schrader I, Janni W, Rack B, Jueckstock J, Kost B, deGregorio A, DeGregorio N, Bekes I, Widschwendter P, Schochter F, Ernst K, Scholz C, Bauer E, Aivazova-Fuchs V, Weissenbacher T, Friedl T. Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study. *Breast* 2018; 44:81–89.

Bekes I, deGregorio A, De Waal A, Nerlich A, deWaal J, Janni W, Ebner F. Review on current treatment options for lesions of uncertain malignant potential (B3 lesions) of the breast: do B3 papillary lesions need to be removed in any case by open surgery?. *Arch Gynecol Obstet* 2018; 300:481–484.

Ebner F, Wiedenmann S, Bekes I, Janni W, De Gregorio N, De Gregorio A. Results of an internal audit on the survival of patients with uterine sarcoma. *J Turk Ger Gynecol Assoc* 2018; 20:15–22.

Ebner F, Friedl T, De Gregorio A, Lato K, Bekes I, Janni W, De Gregorio N. Seroma in breast surgery: all the surgeons fault?. *Arch Gynecol Obstet* 2018; 298:951–959.

Lato K, Bekes I, Widschwendter P, Friedl T, Janni W, Reister F, Froeba G, Friebe-Hoffmann U. Hypotension due to spinal anesthesia influences fetal circulation in primary caesarean sections. *Arch Gynecol Obstet* 2018; 297:667–674.

Widschwendter P, Bauer E, De Gregorio N, Bekes I, Janni W, Scholz C, Friedl T. Influence of Prognostic Factors on Lymph Node Involvement in Endometrial Cancer: A Single-Center Experience. *Int J Gynecol Cancer* 2018; 28:1145–1152.

Bekes I, Haunerding V, Sauter R, Holzheu I, Janni W, Wöckel A, Wulff C. Slit2/Robo4 Signaling: Potential Role of a VEGF-Antagonist Pathway to Regulate Luteal Permeability. *Geburtshilfe Frauenheilkd* 2017; 77:73–80.

Ebner F, Janni W, Bekes I, Lato K, Fink V, Wiegel T, Friedl T, Bottke D, Schramm A, De Gregorio N. Comparison of seroma production in breast conserving surgery with or without intraoperative radiotherapy as tumour bed boost. *Arch Gynecol Obstet* 2016; 294:861–6.

Bekes I, Friedl T, Köhler T, Möbus V, Janni W, Wöckel A, Wulff C. Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer?. *Mol Cancer* 2016; 15:13.

Gundelach T, Rodewald M, Bekes I, Janni W, Hancke K. [Metformin for the treatment of polycystic ovary syndrome]. *Med Monatsschr Pharm* 2016; 39:75-8.

Widschwendter P, Jueckstock J, Neugebauer J, Trapp E, Fasching P, Beckmann M, Schneeweiss A, Schrader I, Rack B, Janni W, Andergassen U, Kost B, Friedl T, Schwentner L, DeGregorio N, Jaeger B, Schramm A, Bekes I, Deniz M, Lato K, Weissenbacher T, Scholz C. The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial. *Breast Cancer Res* 2015; 17:129.

Herr D, Bekes I, Wulff C. Regulation of endothelial permeability in the primate corpora lutea: implications for ovarian hyperstimulation syndrome. *Reproduction* 2014; 149:R71-9.

Herr D, Bekes I, Wulff C. Regulation of Endothelial Permeability in the Corpus Luteum: A Review of the Literature. *Geburtshilfe Frauenheilkd* 2013; 73:1107-1111.

Herr D, Bekes I, Wulff C. Local Renin-Angiotensin system in the reproductive system. *Front Endocrinol (Lausanne)* 2013; 4:150.

Herr D, Sallmann A, Bekes I, Konrad R, Holzheu I, Kreienberg R, Wulff C. VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 5. *Gynecol Oncol* 2012; 127:210-6.

## Projects (3)

### **MEthods for Localization of Different types of breast lesions**

*Clinical Studies - Jan 1, 2023 - Dec 31, 2026*

*Ongoing*

### **Mind-Body Online Therapie im somatischen Setting – Teilprojekt: Onkologische Gynäkologie**

*Clinical Studies - Jan 1, 2022 - Feb 29, 2024*

*Aborted*

### **Tailored AXILLary Surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS)**

*Clinical Studies - Jul 30, 2018 - Dec 12, 2030*

*Ongoing*